17 results on '"Stadtmauer, Edward A"'
Search Results
2. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
3. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma
4. Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment
5. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI
6. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
7. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkinʼs lymphoma or multiple myeloma
8. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
9. Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
10. Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents
11. Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality
12. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis
13. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
14. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation
15. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas
16. Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34 + hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma
17. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.